Condition: Undifferentiated Pleomorphic Sarcoma · Myxofibrosarcoma · Sponsor: BioAtla, Inc.
The objective of this study is to assess the safety and efficacy of mecbotamab vedotin (BA3011) in solid tumors.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| The University of Arizona Cancer Center | Tucson, Arizona, United States | — |
| Children's Hospital Los Angeles | Los Angeles, California, United States | — |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | — |
| Tower Hematology Oncology Medical Group | Los Angeles, California, United States | — |
| Precision NextGen Oncology | Los Angeles, California, United States | — |
| UCSF Medical Center - Cancer Immunotherapy Clinic (CIC) | San Francisco, California, United States | — |
| University of Colorado | Aurora, Colorado, United States | — |
| Sarah Cannon Research Institute at Health One | Denver, Colorado, United States | — |
| Children's Research Institute | Washington D.C., District of Columbia, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| Norton Cancer Institute | Louisville, Kentucky, United States | — |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03425279